NON-SMALL CELL LUNG CANCER RECURRENT

This adverse event was reported 283 times

These drugs are most commonly taken by patients reporting NON-SMALL CELL LUNG CANCER RECURRENT:

# Drug Count
0 DURVALUMAB 64
1 CARBOPLATIN 45
2 OSIMERTINIB 44
3 PACLITAXEL 29
4 PEMBROLIZUMAB 28
5 PACLITAXEL (AIBUMIN-BOUND) 27
6 PEMETREXED DISODIUM 27
7 PEMETREXED 19
8 GEFITINIB 18
9 NIVOLUMAB 18
See all common drugs associated with NON-SMALL CELL LUNG CANCER RECURRENT

NON-SMALL CELL LUNG CANCER RECURRENT is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 AMIVANTAMAB AND HYALURONIDASE-LPUJ (HUMAN RECOMBINANT) 1 0.0033
1 DURVALUMAB 64 0.0030
2 CAPMATINIB 6 0.0025
3 MEXILETINE HYDROCHLORIDE 1 0.0024
4 LAZERTINIB 2 0.0023
5 AMOXAPINE 1 0.0021
6 GEFITINIB 18 0.0020
7 BRIGATINIB 7 0.0019
8 SOTORASIB 6 0.0017
9 TREMELIMUMAB 7 0.0016
See all drugs enriched for association with NON-SMALL CELL LUNG CANCER RECURRENT